PortalPublikationenAllogeneic Hematopoietic Cell Transplantation in Patients Ag...

Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia

Standard

Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. / Rice, Carmel; Eikema, Dirk-Jan; Marsh, Judith C W; Knol, Cora; Hebert, Kyle; Putter, Hein; Peterson, Eefke; Deeg, H Joachim; Halkes, Stijn; Pidala, Joseph; Anderlini, Paolo; Tischer, Johanna; Kroger, Nicolaus; McDonald, Andrew; Antin, Joseph H; Schaap, Nicolaas P; Hallek, Michael; Einsele, Herman; Mathews, Vikram; Kapoor, Neena; Boelens, Jaap-Jan; Mufti, Ghulam J; Potter, Victoria; Pefault de la Tour, Régis; Eapen, Mary; Dufour, Carlo.

in: BIOL BLOOD MARROW TR, Jahrgang 25, Nr. 3, 03.2019, S. 488-495.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Rice, C, Eikema, D-J, Marsh, JCW, Knol, C, Hebert, K, Putter, H, Peterson, E, Deeg, HJ, Halkes, S, Pidala, J, Anderlini, P, Tischer, J, Kroger, N, McDonald, A, Antin, JH, Schaap, NP, Hallek, M, Einsele, H, Mathews, V, Kapoor, N, Boelens, J-J, Mufti, GJ, Potter, V, Pefault de la Tour, R, Eapen, M & Dufour, C 2019, 'Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia', BIOL BLOOD MARROW TR, Jg. 25, Nr. 3, S. 488-495. https://doi.org/10.1016/j.bbmt.2018.08.029

APA

Rice, C., Eikema, D-J., Marsh, J. C. W., Knol, C., Hebert, K., Putter, H., Peterson, E., Deeg, H. J., Halkes, S., Pidala, J., Anderlini, P., Tischer, J., Kroger, N., McDonald, A., Antin, J. H., Schaap, N. P., Hallek, M., Einsele, H., Mathews, V., ... Dufour, C. (2019). Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. BIOL BLOOD MARROW TR, 25(3), 488-495. https://doi.org/10.1016/j.bbmt.2018.08.029

Vancouver

Rice C, Eikema D-J, Marsh JCW, Knol C, Hebert K, Putter H et al. Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. BIOL BLOOD MARROW TR. 2019 Mär;25(3):488-495. https://doi.org/10.1016/j.bbmt.2018.08.029

Bibtex

@article{660d8dd76ba44e07afc1becb2f0b7e18,
title = "Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia",
abstract = "We report on 499 patients with severe aplastic anemia aged ≥ 50years who underwent hematopoietic cell transplantation (HCT) from HLA-matched sibling (n = 275, 55%) or HLA-matched (8/8) unrelated donors (n = 187, 37%) between 2005 and 2016. The median age at HCT was 57.8 years; 16% of patients were 65 to 77years old. Multivariable analysis confirmed higher mortality risks for patients with performance score less than 90% (hazard ratio [HR], 1.41; 95% confidence interval [CI], 1.03 to 1.92; P = .03) and after unrelated donor transplantation (HR, 1.47; 95% CI, 1 to 2.16; P = .05). The 3-year probabilities of survival for patients with performance scores of 90 to 100 and less than 90 after HLA-matched sibling transplant were 66% (range, 57% to 75%) and 57% (range, 47% to 76%), respectively. The corresponding probabilities after HLA-matched unrelated donor transplantation were 57% (range, 48% to 67%) and 48% (range, 36% to 59%). Age at transplantation was not associated with survival, but grades II to IV acute graft-versus-host disease (GVHD) risks were higher for patients aged 65years or older (subdistribution HR [sHR], 1.7; 95% confidence interval, 1.07 to 2.72; P = .026). Chronic GVHD was lower with the GVHD prophylaxis regimens calcineurin inhibitor (CNI) + methotrexate (sHR, .52; 95% CI, .33 to .81; P = .004) and CNI alone or with other agents (sHR, .27; 95% CI, .14 to .53; P < .001) compared with CNI + mycophenolate. Although donor availability is modifiable only to a limited extent, choice of GVHD prophylaxis and selection of patients with good performance scores are key for improved outcomes.",
keywords = "Journal Article",
author = "Carmel Rice and Dirk-Jan Eikema and Marsh, {Judith C W} and Cora Knol and Kyle Hebert and Hein Putter and Eefke Peterson and Deeg, {H Joachim} and Stijn Halkes and Joseph Pidala and Paolo Anderlini and Johanna Tischer and Nicolaus Kroger and Andrew McDonald and Antin, {Joseph H} and Schaap, {Nicolaas P} and Michael Hallek and Herman Einsele and Vikram Mathews and Neena Kapoor and Jaap-Jan Boelens and Mufti, {Ghulam J} and Victoria Potter and {Pefault de la Tour}, R{\'e}gis and Mary Eapen and Carlo Dufour",
note = "Copyright {\textcopyright} 2018 Elsevier Ltd. All rights reserved.",
year = "2019",
month = mar,
doi = "10.1016/j.bbmt.2018.08.029",
language = "English",
volume = "25",
pages = "488--495",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia

AU - Rice, Carmel

AU - Eikema, Dirk-Jan

AU - Marsh, Judith C W

AU - Knol, Cora

AU - Hebert, Kyle

AU - Putter, Hein

AU - Peterson, Eefke

AU - Deeg, H Joachim

AU - Halkes, Stijn

AU - Pidala, Joseph

AU - Anderlini, Paolo

AU - Tischer, Johanna

AU - Kroger, Nicolaus

AU - McDonald, Andrew

AU - Antin, Joseph H

AU - Schaap, Nicolaas P

AU - Hallek, Michael

AU - Einsele, Herman

AU - Mathews, Vikram

AU - Kapoor, Neena

AU - Boelens, Jaap-Jan

AU - Mufti, Ghulam J

AU - Potter, Victoria

AU - Pefault de la Tour, Régis

AU - Eapen, Mary

AU - Dufour, Carlo

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2019/3

Y1 - 2019/3

N2 - We report on 499 patients with severe aplastic anemia aged ≥ 50years who underwent hematopoietic cell transplantation (HCT) from HLA-matched sibling (n = 275, 55%) or HLA-matched (8/8) unrelated donors (n = 187, 37%) between 2005 and 2016. The median age at HCT was 57.8 years; 16% of patients were 65 to 77years old. Multivariable analysis confirmed higher mortality risks for patients with performance score less than 90% (hazard ratio [HR], 1.41; 95% confidence interval [CI], 1.03 to 1.92; P = .03) and after unrelated donor transplantation (HR, 1.47; 95% CI, 1 to 2.16; P = .05). The 3-year probabilities of survival for patients with performance scores of 90 to 100 and less than 90 after HLA-matched sibling transplant were 66% (range, 57% to 75%) and 57% (range, 47% to 76%), respectively. The corresponding probabilities after HLA-matched unrelated donor transplantation were 57% (range, 48% to 67%) and 48% (range, 36% to 59%). Age at transplantation was not associated with survival, but grades II to IV acute graft-versus-host disease (GVHD) risks were higher for patients aged 65years or older (subdistribution HR [sHR], 1.7; 95% confidence interval, 1.07 to 2.72; P = .026). Chronic GVHD was lower with the GVHD prophylaxis regimens calcineurin inhibitor (CNI) + methotrexate (sHR, .52; 95% CI, .33 to .81; P = .004) and CNI alone or with other agents (sHR, .27; 95% CI, .14 to .53; P < .001) compared with CNI + mycophenolate. Although donor availability is modifiable only to a limited extent, choice of GVHD prophylaxis and selection of patients with good performance scores are key for improved outcomes.

AB - We report on 499 patients with severe aplastic anemia aged ≥ 50years who underwent hematopoietic cell transplantation (HCT) from HLA-matched sibling (n = 275, 55%) or HLA-matched (8/8) unrelated donors (n = 187, 37%) between 2005 and 2016. The median age at HCT was 57.8 years; 16% of patients were 65 to 77years old. Multivariable analysis confirmed higher mortality risks for patients with performance score less than 90% (hazard ratio [HR], 1.41; 95% confidence interval [CI], 1.03 to 1.92; P = .03) and after unrelated donor transplantation (HR, 1.47; 95% CI, 1 to 2.16; P = .05). The 3-year probabilities of survival for patients with performance scores of 90 to 100 and less than 90 after HLA-matched sibling transplant were 66% (range, 57% to 75%) and 57% (range, 47% to 76%), respectively. The corresponding probabilities after HLA-matched unrelated donor transplantation were 57% (range, 48% to 67%) and 48% (range, 36% to 59%). Age at transplantation was not associated with survival, but grades II to IV acute graft-versus-host disease (GVHD) risks were higher for patients aged 65years or older (subdistribution HR [sHR], 1.7; 95% confidence interval, 1.07 to 2.72; P = .026). Chronic GVHD was lower with the GVHD prophylaxis regimens calcineurin inhibitor (CNI) + methotrexate (sHR, .52; 95% CI, .33 to .81; P = .004) and CNI alone or with other agents (sHR, .27; 95% CI, .14 to .53; P < .001) compared with CNI + mycophenolate. Although donor availability is modifiable only to a limited extent, choice of GVHD prophylaxis and selection of patients with good performance scores are key for improved outcomes.

KW - Journal Article

U2 - 10.1016/j.bbmt.2018.08.029

DO - 10.1016/j.bbmt.2018.08.029

M3 - SCORING: Journal article

C2 - 30194027

VL - 25

SP - 488

EP - 495

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 3

ER -